Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for people with diabetes and the largest contributor to the direct and indirect costs of diabetes. Approximately 65% of all CVD deaths in Australia occur in people with diabetes or prediabetes.
Over the last few years, the management of type 2 diabetes has rapidly grown more complex. Recent developments include new medicines, emerging clinical trial results that provide cardiovascular (CV) outcome data related to blood glucose-lowering medicines, and an update to clinical guidelines. Now, more than ever, a clear, stepped approach is necessary to navigate the plethora of options available and reduce risk of microvascular and macrovascular complications.
Join our multidisciplinary panel of experts for a webinar discussion on the prevention of CV events in patients with both type 2 diabetes and CVD. Discussion will cover:
- Evidence-based strategies to reduce CV risk for patients with diabetes and CVD
- Advice on how to individualise choice of blood glucose-lowering agents
- The latest Australian blood glucose treatment algorithm for type 2 diabetes
- An update on the latest CV outcome trial data and how this impacts your practice